Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Outlook Therapeutics Logo
Outlook Therapeutics Growth Score
64
CB Rank
15116
Heat Score
75
Outlook Therapeutics is a biopharmaceutical company that develops ophthalmic formulations.
Founded
obfuscation
PublicPost-IPO Equity Iselin, New Jersey, United States11-50 outlooktherapeutics.com
Biopharma
Biotechnology
Pharmaceutical
Therapeutics
Overview

Outlook Therapeutics
Total Funding
obfuscation
Growth Score
64
Heat Score
75

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score64
-6 pts
in past quarter
Heat Score 75
26 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
+2 more milestones
See more interactive data and historical milestones on desktop for the best experience

About Outlook Therapeutics

CB Rank
15116
Outlook Therapeutics is a biopharmaceutical company that develops ophthalmic formulations.
Founded
obfuscation
PublicPost-IPO Equity Iselin, New Jersey, United States11-50 outlooktherapeutics.com
Biopharma
Biotechnology
Pharmaceutical
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation

Key People

  • Photo of Tony Moses
    Tony Moses: Executive Director of Physician Relations
    Past Role: Oraya Therapeutics, VP - Global Sales and Distribution
  • Photo of Surendra Sharma
    Surendra Sharma: Senior Vice President

Details

Legal Name Outlook Therapeutics, Inc.
Also Known As Oncobiologics, Oncobiologics Inc.
Operating Status Active
Stock Symbol  NASDAQ:OTLK
Company Type For Profit
Founders  Pankaj Mohan
About the Company
Outlook Therapeutics develops an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion. Their ophthalmic formulations also use in treating retinal diseases.
Phone Number +1 609 619 3990
Contact Email info@outlooktherapeutics.com
Predictions & Insights

Growth Insight

See this Growth Insight
Outlook Therapeutics is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

ONS-5010 / LYTENAVA™
An ophthalmic formulation of bevacizumab for treating retinal diseases such as wet age-related macular degeneration (wet AMD).
LYTENAVA real-world evidence study in Germany
A real-world evidence study in Germany evaluating LYTENAVA in routine clinical practice to support reimbursement and market access.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 17
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Outlook Therapeutics Logo
Post-IPO Equity - Outlook Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Outlook Therapeutics Logo
Post-IPO Equity - Outlook Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Outlook Therapeutics Logo
Post-IPO Equity - Outlook Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Outlook Therapeutics Logo
Post-IPO Equity - Outlook Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Outlook Therapeutics Logo
Post-IPO Equity - Outlook Therapeutics
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 17
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Outlook Therapeutics Logo
Post-IPO Equity - Outlook Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Outlook Therapeutics Logo
Post-IPO Equity - Outlook Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Outlook Therapeutics Logo
Post-IPO Equity - Outlook Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Outlook Therapeutics Logo
Post-IPO Equity - Outlook Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Outlook Therapeutics Logo
Post-IPO Equity - Outlook Therapeutics
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Atlas Sciences Logo
Atlas Sciences
Yes
Post-IPO Debt - Outlook Therapeutics Logo
Post-IPO Debt - Outlook Therapeutics
—
Atlas Sciences Logo
Atlas Sciences
Yes
Post-IPO Debt - Outlook Therapeutics Logo
Post-IPO Debt - Outlook Therapeutics
—
Atlas Sciences Logo
Atlas Sciences
Yes
Post-IPO Debt - Outlook Therapeutics Logo
Post-IPO Debt - Outlook Therapeutics
—
Atlas Sciences Logo
Atlas Sciences
Yes
Post-IPO Debt - Outlook Therapeutics Logo
Post-IPO Debt - Outlook Therapeutics
—
Atlas Sciences Logo
Atlas Sciences
Yes
Post-IPO Debt - Outlook Therapeutics Logo
Post-IPO Debt - Outlook Therapeutics
—
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 12 Board Members and Advisors 1

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 27, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

3,207
-0.59%
 in past month

IT Spend

$32.7KThis year, Outlook Therapeutics is projected to spend $32.7K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Conflict Resolution Logo
Conflict Resolution
71

Actively Used Products

17Outlook Therapeutics uses 17 technology products and services including HTML5, Lightbox, and  Vimeo, according to G2 Stack.

Active Website Tech Count

42Outlook Therapeutics is actively using 42 technologies for its website, according to BuiltWith. These include Common Crawl, IPhone / Mobile Compatible, and  Viewport Meta.
Sub-Organizations
Frequently Asked Questions

Where is Outlook Therapeutics's headquarters? Outlook Therapeutics is located in Iselin, New Jersey, United States.Who invested in Outlook Therapeutics? Outlook Therapeutics has 18 investors including Atlas Sciences and  Syntone Ventures.When was the last funding round for Outlook Therapeutics? Outlook Therapeutics closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Outlook Therapeutics's competitors? Alternatives and possible competitors to Outlook Therapeutics may include Opus Genetics, Atsena Therapeutics, and  Nanoscope Therapeutics.How much funding has Outlook Therapeutics raised to date? Outlook Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(3237dbc 1)
|